期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Reports of cardiac adverse events from oncology clinical trials often are at variance with reports derived from clinical observations or data-base rev......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Background Anthracycline chemotherapy and thoracic radiation therapy (RT) are known causes of cardiomyopathy among cancer survivors, however, manageme......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Background Dedicated cardio-oncology services are emerging rapidly around the world in order to provide cardiovascular care (CV) for cancer patients. ......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
We report the case of a 59-year-old female patient with no previous cardiovascular disease treated for Breast cancer with Capecitabine. Shortly after ......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Background Malignancy is known to be a major cause of death in adult congenital heart disease (ACHD). However, data regarding cardiovascular and cance......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Background Programmed death-1 (PD-1) and programmed death- ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab and atezolizumab, are major c......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Background The full range of cardiovascular complications related to the use of Immune checkpoint inhibitors (ICI) is not fully understood. We aim to ......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Neo(adjuvant) systemic treatment regimens containing anthracyclines such as doxorubicin cause a significant risk of heart failure. These regimens are ......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Paclitaxel-induced cardiac ischemia is a rare but life-threatening complication. Although it may be difficult to distinguish from hypersensitivity or ......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Background Androgen deprivation therapy (ADT) and radiotherapy (RT) are the mainstay treatment for localized prostate cancer and recurrence after surg......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Background Radiation-induced myocardial fibrosis increases heart failure (HF) risk and is associated with a restrictive cardiomyopathy phenotype. The ......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Background Chimeric antigen receptor T-cell (CART) therapy is a form of cellular immunotherapy used to treat hematologic malignancies. Major adverse c......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Cardiovascular diseases and cancer continue to be the two leading causes of death in the United States. While innovations in artificial intelligence, ......
期刊： CARDIO-ONCOLOGY, 2022; 8 (1)
Anticancer therapy has the potential to cause unwanted cardiovascular side effects. Utilization of radiation therapy to treat tumors near the heart ca......
